血管认知障碍和痴呆症:机制,治疗和未来的方向
Vincent Chung Tong Mok1, Yuan Cai1, Hugh S Markus2
1Lau Tat-chuen Research Centre of Brain Degenerative Diseases in Chinese, Therese Pei Fong Chow Research Centre for Prevention of Dementia, Lui Che Woo Institute of Innovative Medicine, Gerald Choa Neuroscience Institute, Li Ka Shing Institute of Health Science, Division of Neurology, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China.
概括
血管认知障碍 (VCI) 影响着2000万人,导致痴呆. 管理重点是预防中风和控制血管风险因素,需要研究新疗法.
科学领域:
- 神经学 神经学
- 血管医学 血管医学
- 老年学是一门学科.
背景情况:
- 痴呆症影响全球5000万,预计到2050年将增加三倍.
- 血管病理导致20%的痴呆病例和20%的混合痴呆.
- 血管认知障碍 (VCI) 涵盖了一系列由脑血管疾病引起的认知问题.
研究的目的:
- 审查血管认知障碍 (VCI) 的机制和管理.
- 为了突出脑血管疾病和阿尔茨海默病之间的联系.
- 强调需要增加对VCI的研究和资金.
主要方法:
- 审查关于VCI机制和管理的现有文献.
- 讨论慢性脑血管疾病,包括大脑小血管疾病.
- 对脑血管疾病和阿尔茨海默病之间的相互作用进行分析.
主要成果:
- 脑血管损伤可以发生在中风后的急性或由于慢性脑血管疾病的潜伏性.
- 脑血管疾病加剧了阿尔茨海默病的进展,并可能导致其病因.
- 目前的VCI管理优先考虑中风预防,血管风险因素控制 (特别是高血压) 和再输血疗法.
结论:
- 风险性肺炎是一个显著且日益严重的公共卫生问题,特别是在低收入和中等收入国家.
- 现有的有效治疗方法很少,需要新的治疗策略.
- 将认知终点整合到心血管试验中,并增加研究重点至关重要.
相关概念视频
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Alzheimer's Disease: Overview
452
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
452
Dementia
107
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
107
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
108
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
108
Cognitive Development During Adulthood
68
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
68


